Shots: Insilico Medicine and SK Biopharmaceuticals entered a research and development collaboration to discover AI-enabled therapies for neuroimmune disorders of the central nervous system (CNS), including neuroinflammatory, neurodegenerative, and rare neurological diseases Under the agreement, Insilico will utilize its proprietary Pharma.AI platform, covering target validation, generative chemistry, and molecule optimization, alongside its preclinical drug discovery…